Sign In

Matthew Rossiter

Partner at Fenwick & West LLP

Matthew Rossiter is a partner at Fenwick & West LLP, specializing in representing fast-growing innovative businesses in the technology and life sciences sectors.24 He was named Venture Capital Attorney of the Year for his outstanding work with life sciences companies.3 Rossiter co-leads Fenwick's Life Sciences group alongside partners Stefano Quintini and Melanie Mayer.1

Under Rossiter's leadership, Fenwick's Life Sciences group has:

  1. Advised on over 400 partnering and licensing matters in the last five years
  2. Handled more than 180 life sciences venture financing transactions
  3. Guided significant deals, including Chinook Therapeutics' multi-billion acquisition by Novartis AG and DICE Therapeutics' $2.4 billion acquisition by Eli Lilly1

Rossiter's expertise spans various stages of company growth, from entrepreneurs with a vision to established later-stage companies.2 His work has contributed to Fenwick's recognition as a finalist for Firm of the Year in multiple categories, including venture capital.1

Based in the San Francisco Bay Area, Rossiter plays a key role in Fenwick's reputation as a leading law firm for technology and life sciences companies.42

Highlights

Elegen's $35 Million Series B Financing Round – Global Legal Chronicle - Global Legal Chronicle
BioAge's $170 Million Series D Financing Round – Global Legal Chronicle - Global Legal Chronicle

Related Questions

What are some of the notable deals Matthew Rossiter has worked on?
How did Matthew Rossiter and Stefano Quintini contribute to Fenwick's Life Sciences group?
What makes Matthew Rossiter's approach to fiduciary litigation unique?
Can you provide more details about the Chinook Therapeutics and DICE Therapeutics acquisitions?
What are the key achievements of Fenwick & West's Life Sciences group under Matthew Rossiter's leadership?
Matthew Rossiter
Matthew Rossiter, photo 1
Matthew Rossiter, photo 2
Add to my network

Location

San Francisco Bay Area